← Leaderboards
Gary S. Gilkeson
Medical University Of South Carolina
$15,374,032
Attributed
$17,604,196
Total exposure
19
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,555,611 · 19
VA$0 · 2
By mechanism
U01$6,700,568 · 2
P60$5,980,813 · 2
R01$5,859,209 · 3
P30$4,826,441 · 2
T32$3,881,598 · 1
R34$255,067 · 1
Top collaborators
- James C Oates6 shared
- Diane L Kamen3 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Xian Zhang$1,937,483
- Tamara K Nowling$698,616
- James C Oates$6,188,464
- Hideharu Sekine$405,625
Others in their field
Top investigators on “Systemic Lupus Erythematosus”
- Ignacio E. Sanz · University Of Rochester$57,737,718
- George C Tsokos · Beth Israel Deaconess Medical Center$37,219,358
- David Wofsy · University Of California, San Francisco$36,472,228
- Betty Diamond · Feinstein Institute For Medical Research$32,406,714
- John Barker Harley · Cincinnati Va Medical Center Research$30,355,689
- Patrick M Gaffney · University Of Minnesota Twin Cities$27,964,103
Research focus
Systemic Lupus ErythematosusLupusClinical ResearchBaseFundingGrantPathogenesisWomanAfrican AmericanResponseResearch PersonnelFamilyMediatingMorbidity - Disease RateCellsInflammatoryHuman SubjectReportingInnovationGenesSamplingMedicalGeneticResources
Grant awards (104)
A Phase II Controlled Trial of Allogeneic Mesenchymal Stromal Cells for the Treatment of Refractory Lupus (MiSLE)$1,459,720
U01 · FY2025 · AI · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$242,371
T32 · FY2025 · AR · contact PI
A Phase II Controlled Trial of Allogeneic Mesenchymal Stromal Cells for the Treatment of Refractory Lupus (MiSLE)$1,225,013
U01 · FY2024 · AI · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$186,131
T32 · FY2024 · AR · contact PI
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus$464,370
U01 · FY2023 · AI · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$260,222
T32 · FY2023 · AR · contact PI
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus$707,818
U01 · FY2022 · AI · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$240,939
T32 · FY2022 · AR · contact PI
Role of Gut Microbial Translocation in Initiating Autoimmunity$0
I01 · FY2022 · VA · contact PI
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus$707,818
U01 · FY2021 · AI · contact PI
Improving Minority Health in Rheumatic Diseases$705,060
P30 · FY2021 · AR · contact PI
Administrative Core$134,312
P30 · FY2021 · AR · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$130,945
T32 · FY2021 · AR · contact PI
Role of Gut Microbial Translocation in Initiating Autoimmunity$0
I01 · FY2021 · VA · contact PI
Role of Gut Microbial Translocation in Initiating Autoimmunity$0
I01 · FY2021 · VA · contact PI
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus$707,818
U01 · FY2020 · AI · contact PI
Improving Minority Health in Rheumatic Diseases$706,417
P30 · FY2020 · AR · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$268,646
T32 · FY2020 · AR · contact PI
Administrative Core$134,312
P30 · FY2020 · AR · contact PI
Improving Minority Health in Rheumatic Diseases$714,284
P30 · FY2019 · AR · contact PI
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus$707,818
U01 · FY2019 · AI · contact PI
Improving Minority Health in Rheumatic Diseases$550,503
P30 · FY2019 · AR · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$204,893
T32 · FY2019 · AR · contact PI
Administrative Core$134,312
P30 · FY2019 · AR · contact PI
Role of Gut Microbial Translocation in Initiating Autoimmunity$0
I01 · FY2019 · VA · contact PI
Improving Minority Health in Rheumatic Diseases$734,003
P30 · FY2018 · AR · contact PI
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus$720,193
U01 · FY2018 · AI · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$175,377
T32 · FY2018 · AR · contact PI
Administrative Core$134,312
P30 · FY2018 · AR · contact PI
Sex Differences in Gut Permeability; Impact on Autoimmunity$0
I01 · FY2018 · VA · contact PI
Improving Minority Health in Rheumatic Diseases$744,614
P30 · FY2017 · AR · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$219,398
T32 · FY2017 · AR · contact PI
Administrative Core$134,312
P30 · FY2017 · AR · contact PI
Sex Differences in Gut Permeability; Impact on Autoimmunity$0
I01 · FY2017 · VA · contact PI
MCRC for Rheumatic Diseases in African Americans$1,158,325
P60 · FY2016 · AR · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$223,928
T32 · FY2016 · AR · contact PI
Sex Differences in Gut Permeability; Impact on Autoimmunity$0
I01 · FY2016 · VA · contact PI
MCRC for Rheumatic Diseases in African Americans$1,087,495
P60 · FY2015 · AR · contact PI
MCRC for Rheumatic Diseases in African Americans$71,262
P60 · FY2015 · AR · contact PI
Sex Differences in Gut Permeability; Impact on Autoimmunity$0
I01 · FY2015 · VA · contact PI
MCRC for Rheumatic Diseases in African Americans$1,114,587
P60 · FY2014 · AR · contact PI
Mesenchymal Stem Cell Therapy for Active Systemic Lupus Erythematosus$255,067
R34 · FY2014 · AI · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$220,322
T32 · FY2014 · AR · contact PI
MCRC for Rheumatic Diseases in African Americans$1,095,546
P60 · FY2013 · AR · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$215,828
T32 · FY2013 · AR · contact PI
MCRC for Rheumatic Diseases in African Americans$99,912
P60 · FY2013 · AR · contact PI
Role of Estrogen Receptors in Lupus-Modulators of the Inflammatory Response$0
I01 · FY2013 · VA · contact PI
MCRC for Rheumatic Diseases in African Americans$1,169,407
P60 · FY2012 · AR · contact PI
Role of reactive intermediates in lupus nephritis$324,650
R01 · FY2012 · AR
Training Grant in Inflammatory and Fibrosing Diseases$155,318
T32 · FY2012 · AR · contact PI
Role of Estrogen Receptors in Lupus-Modulators of the Inflammatory Response$0
I01 · FY2012 · VA · contact PI
Role of reactive intermediates in lupus nephritis$275,184
R01 · FY2011 · AR
Training Grant in Inflammatory and Fibrosing Diseases$192,984
T32 · FY2011 · AR · contact PI
Role of reactive intermediates in lupus nephritis$37,981
R01 · FY2011 · AR
Role of Estrogen Receptors in Lupus-Modulators of the Inflammatory Response$0
I01 · FY2011 · VA · contact PI
Role of reactive intermediates in lupus nephritis$286,650
R01 · FY2010 · AR · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$194,078
T32 · FY2010 · AR · contact PI
Role of reactive intermediates in lupus nephritis$293,899
R01 · FY2009 · AR · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$170,484
T32 · FY2009 · AR · contact PI
Role of Estrogen Receptors in Lupus-Modulators of the Inflammatory Response$0
I01 · FY2009 · VA · contact PI
Role of reactive intermediates in lupus nephritis$302,164
R01 · FY2008 · AR · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$155,869
T32 · FY2008 · AR · contact PI
SYSTEMIC LUPUS ERYTHEMATOSUS DATABASE PROJECT$13,950
M01 · FY2008 · RR · contact PI
Nitric oxide in systemic lupus erythematosus$318,862
R01 · FY2007 · AR · contact PI
Genetic & Environmental Influences on the Development & Progression of Lupus...$184,279
P60 · FY2007 · AR · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$63,975
T32 · FY2007 · AR · contact PI
SYSTEMIC LUPUS ERYTHEMATOSUS DATABASE PROJECT$36,398
M01 · FY2007 · RR · contact PI
Nitric oxide in systemic lupus erythematosus$328,605
R01 · FY2006 · AR · contact PI
Training Grant in Inflammatory and Fibrosing Diseases$180,820
T32 · FY2006 · AR · contact PI
Nitric oxide in systemic lupus erythematosus$289,257
R01 · FY2005 · AR
ROLE OF PPAR GAMMA IN LUPUS NEPHRITIS$239,400
R01 · FY2005 · AR
Training Grant in Inflammatory and Fibrosing Diseases$179,070
T32 · FY2005 · AR
Nitric oxide in systemic lupus erythematosus$41,160
R01 · FY2005 · AR
Nitric oxide in systemic lupus erythematosus$289,501
R01 · FY2004 · AR
ROLE OF PPAR GAMMA IN LUPUS NEPHRITIS$239,400
R01 · FY2004 · AR
ROLE OF COMPLEMENT FACTOR B IN THE PATHOGENESIS OF SLE$232,500
R01 · FY2004 · AI
Intravenous Cyclophosphamide vs. Mycophenolate Mofetil Induction Therapy$1,567
M01 · FY2004 · RR
Nitric oxide in systemic lupus erythematosus$295,611
R01 · FY2003 · AR
ROLE OF PPAR GAMMA IN LUPUS NEPHRITIS$239,400
R01 · FY2003 · AR
ROLE OF COMPLEMENT FACTOR B IN THE PATHOGENESIS OF SLE$232,500
R01 · FY2003 · AI
ROLE OF PPAR GAMMA IN LUPUS NEPHRITIS$239,400
R01 · FY2002 · AR
ROLE OF COMPLEMENT FACTOR B IN THE PATHOGENESIS OF SLE$232,500
R01 · FY2002 · AI
LJP 394 VS PLACEBO IN TREATMENT OF SLE$0
M01 · FY2002 · RR
EFFECT OF DMP 777UPON JOINT MANIFESTATIONS IN SLE$0
M01 · FY2002 · RR
TRIAL OF LJP 394 IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
ROLE OF COMPLEMENT FACTOR B IN THE PATHOGENESIS OF SLE$232,500
R01 · FY2001 · AI
NITRIC OXIDE AND SYSTEMIC LUPUS ERYTHEMATOSUS$229,054
R01 · FY2001 · AR
ROLE OF PPAR GAMMA IN LUPUS NEPHRITIS$209,475
R01 · FY2001 · AR
EFFECT OF DMP 777UPON JOINT MANIFESTATIONS IN SLE$0
M01 · FY2001 · RR
EFFECT OF DMP 777UPON JOINT MANIFESTATIONS IN SLE$0
M01 · FY2001 · RR
EFFECT OF DMP 777UPON JOINT MANIFESTATIONS IN SLE$0
M01 · FY2001 · RR
TRIAL OF LJP 394 IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
TRIAL OF LJP 394 IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
TRIAL OF LJP 394 IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
LJP 394 VS PLACEBO IN TREATMENT OF SLE$0
M01 · FY2001 · RR
LJP 394 VS PLACEBO IN TREATMENT OF SLE$0
M01 · FY2001 · RR
LJP 394 VS PLACEBO IN TREATMENT OF SLE$0
M01 · FY2001 · RR
ROLE OF COMPLEMENT FACTOR B IN THE PATHOGENESIS OF SLE$239,000
R01 · FY2000 · AI
NITRIC OXIDE AND SYSTEMIC LUPUS ERYTHEMATOSUS$210,556
R01 · FY2000 · AR
LJP 394 VS PLACEBO IN TREATMENT OF SLE$0
M01 · FY2000 · RR
TRIAL OF LJP 394 IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR
PHASE 11 TRIAL OF LJP 394 IN PATIENTS WITH SLE$0
M01 · FY2000 · RR
PHASE 111 TRIAL OF LJP 394 IN PATIENTS WITH SLE$0
M01 · FY2000 · RR
EFFECT OF DMP 777UPON JOINT MANIFESTATIONS IN SLE$0
M01 · FY2000 · RR